These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17467882)

  • 1. Editorial comment on: Prostate cancer characteristics in a multiracial community.
    Karakiewicz PI
    Eur Urol; 2008 Mar; 53(3):539. PubMed ID: 17467882
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: Prostate cancer characteristics in a multiracial community.
    Chun FK
    Eur Urol; 2008 Mar; 53(3):538-9. PubMed ID: 17467881
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer characteristics in a multiracial community.
    Ravery V; Dominique S; Hupertan V; Ben Rhouma S; Toublanc M; Boccon-Gibod L; Boccon-Gibod L
    Eur Urol; 2008 Mar; 53(3):533-8. PubMed ID: 17467885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating racial differences in clinical and pathological features of prostate cancer in South African men.
    Dewar M; Kaestner L; Zikhali Q; Jehle K; Sinha S; Lazarus J
    S Afr J Surg; 2018 Jun; 56(2):54-58. PubMed ID: 30010267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
    Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 7. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Naughton CK; Brawer MK; Flanigan RC; Richie JP; Patel A; Walsh PC; Scardino PT; Lange PH; deKernion JB; Southwick PC; Loveland KG; Parson RE; Gasior GH
    Urology; 2000 Mar; 55(3):372-6. PubMed ID: 10699613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.
    Moses KA; Chen LY; Sjoberg DD; Bernstein M; Touijer KA
    BMC Urol; 2014 Dec; 14():98. PubMed ID: 25495177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer risk groups and comparisons: fruitless or fruitful?
    Gray JR
    J Clin Oncol; 2002 Oct; 20(19):4129; author reply 4129-30. PubMed ID: 12351616
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
    Greene DR
    Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment.
    Carter HB
    Urology; 2009 Sep; 74(3):658; author reply 659. PubMed ID: 19716923
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
    Trpkov K
    Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Semjonow A
    Eur Urol; 2010 Apr; 57(4):629-30. PubMed ID: 19375846
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
    Ciatto S
    Eur Urol; 2010 Apr; 57(4):630. PubMed ID: 19375847
    [No Abstract]   [Full Text] [Related]  

  • 15. Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy Gleason score ≥ 8 via contemporary multi (≥ 12)-core prostate biopsy.
    Hong SK; Oh JJ; Jeong SJ; Jeong CW; Kim IS; Park JM; Byun SS; Choe G; Lee HJ; Lee SE
    BJU Int; 2011 Jul; 108(2):217-22. PubMed ID: 21083642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biopsy specimen features in black and white men with clinically localized prostate cancer.
    Bozeman C; Williams BJ; Whatley T; Crow A; Eastham J
    South Med J; 2000 Apr; 93(4):400-2. PubMed ID: 10798510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
    Pettaway CA; Troncoso P; Ramirez EI; Johnston DA; Steelhammer L; Babaian RJ
    J Urol; 1998 Aug; 160(2):437-42. PubMed ID: 9679893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
    Elliott CS; Shinghal R; Presti JC
    J Urol; 2008 Oct; 180(4):1318-23; discussion 1323-4. PubMed ID: 18707710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial Comment to Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Mearini L
    Int J Urol; 2015 Nov; 22(11):1035-6. PubMed ID: 26303376
    [No Abstract]   [Full Text] [Related]  

  • 20. Racial differences in prostate carcinogenesis. Histologic and clinical observations.
    Fowler JE; Bigler SA
    Urol Clin North Am; 2002 Feb; 29(1):183-91. PubMed ID: 12109344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.